Pentoxifylline
CAS No.
1677687
Reference product
N/A
Polymorphic form
Form I
Therapeutic Area
Cardiovascular system
Status
commercial
EU DMF readiness
✓
US DMF readiness
020976
CEP
✓
Other documentation
Chinese DMF
💉 Available also
in injectable form
Drug description:
Pentoxifylline is a xanthine derivative belongs to vasodilator agent. It is indicated for the treatment of peripheral vascular disease, including intermittent claudication on the basis of chronic occlusive arterial disease of the limbs and for the treatment of acute arterial circulatory disorders of the eye.
It is formulated as extended release tablets for oral route of administration and as solution for injection infusion for intravenous route of administration.
Mechanism of action:
Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).